SCHEDULE: Jorey Chernett Exits IO Biotech Position

Jorey Chernett has filed an exit statement confirming the disposal of all beneficial ownership in IO Biotech, Inc.

Summary

• Jorey Chernett filed an Amendment No. 2 to Schedule 13G.
• The filing serves as an exit statement regarding the Reporting Person's interest in IO Biotech, Inc.
• As of May 19, 2026, the Reporting Person holds 0 shares of the issuer's common stock.
• The Reporting Person no longer maintains any beneficial ownership or voting power in the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting a change in individual shareholding status with no direct impact on company operations.

Positives

• The filing provides clear transparency regarding the complete divestment of the Reporting Person's position.

Negatives

• The complete exit of a shareholder may be perceived as a lack of long-term confidence in the issuer's immediate prospects.

Risks

• Potential market perception issues regarding the departure of a previously identified shareholder.

Future Outlook

No future outlook or guidance is provided in this exit filing.

Industry Context

StockSavvy.ai notes that Schedule 13G exit filings are standard regulatory disclosures when an investor drops below the 5% reporting threshold or divests entirely, and they are generally neutral events unless the investor is a significant institutional activist.

Comparison to Industry Standards

• This filing adheres to standard SEC requirements for reporting changes in beneficial ownership under the Securities Exchange Act of 1934.

Stakeholder Impact

• Minimal impact on shareholders as this represents the exit of an individual investor.

Next Steps

• No further reporting required by this individual regarding IO Biotech, Inc.

Key Dates

Keywords

IO Biotech, Schedule 13G, Divestment, Exit Filing, Jorey Chernett, Common Stock